RedHill Biopharma in Active Talks for Opaganib Collaborations
Summary
RedHill Biopharma is actively discussing potential collaborations to advance its investigational oral drug, Opaganib, including for Ebola outbreak biodefense platforms. This news follows a 6-K filed minutes earlier, which specified discussions with the World Health Organization (WHO) and other partners. For a company that recently received a Nasdaq delisting notice and reported a going concern warning, securing partnerships for a key drug candidate is a critical step towards potential funding and continued development.
At the time of this announcement, RDHL was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.